Bent Benemann Bischoff, (Chairman)
Bent Beneman has received a business education from Copenhagen Business School. His specialties include: corporate development, corporate restructuring, strategic planning, business development, M&A, corporate Finance, financial & economic management including MIS & ERP-systems.
Klaus Bæk Simonsen, Ph.D.
Klaus Bæk Simonsen holds a Ph.D. in organic chemistry from SDU. After research fellow positions at Aarhus University and The Scripps Research Institute in California, Klaus began his professional career at Anadys Pharmaceutical in San Diego, CA, where he worked as a principal scientist for 4 years. Since 2005 Klaus has worked at H. Lundbeck and he is currently divisional director, Medicinal Chemistry Research. Klaus has ten years medicinal chemistry/drug discovery experience which has resulted in the nomination of several preclinical drug candidates. Klaus has contributed to more than 40 patents and publications
Gustaf Iuel-Brockdorff, M.Sc. MBA
Gustaf holds a masters degree in inorganic chemistry from the University of Copenhagen as well as an e-MBA from Centre for Technology, Economics and Management at the Technical University of Denmark. Gustaf started his career as a patent agent for a Danish agency. He then moved on to become purchasing consultant on EU-Tenders for laboratory equipment purchases. For the last 5 five years he has been an investment and portfolio manager at Syddansk Teknologisk Innovation A/S, which main focus area is pre-seed investments.
Karin Verland, MD, CEO
Karin has impressive CEO experience, she is former country manager of Pfizer Denmark, and she has a professional medical background of 20+ years in the Nordic Pharmaceutical Industry. Her experience has been gathered primarily in the fields of Sales, Marketing and General Management.
In addition, Karin has several years of experience as a board member and she is currently a member of the Danish Ethical Board and was former Chairman of the Pharmaceutical Association Lif in Denmark